Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene-signature-derived IC50s/EC50s reflect the potency of causative upstream targets and downstream phenotypes.

Scientific reports - 15 Jun 2020

Renner Steffen, Bergsdorf Christian, Bouhelal Rochdi, Koziczak-Holbro Magdalena, Amati Andrea Marco, Techer-Etienne Valerie, Flotte Ludivine, Reymann Nicole, Kapur Karen, Hoersch Sebastian, Oakeley Edward James, Schuffenhauer Ansgar, Gubler Hanspeter, Lounkine Eugen, Farmer Pierre

Abstract excerpt

Multiplexed gene-signature-based phenotypic assays are increasingly used for the identification and profiling of small molecule-tool compounds and drugs. Here we introduce a method (provided as R-package) for the quantification of the dose-response potency of a gene-signature as EC50 and IC50 values. Two signaling pathways were used as models to validate our methods: beta-adrenergic agonistic activity on cAMP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Agonists
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclic AMP

Share to Dose-Response Relationship, Drug

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to Inhibitory Concentration 50

Share to THP-1 Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 32541899
DOI: 10.1038/s41598-020-66533-5
PMCID: PMC7295968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene-signature-derived IC50s/EC50s reflect the potency of causative upstream targets and downstream phenotypes.PMID 32541899Read ↗

Utilization of genomic signatures to identify phenotype-specific drugs.Semantic proximity Read ↗

Aggregated Compound Biological Signatures Facilitate Phenotypic Drug Discovery and Target Elucidation.Semantic proximity Read ↗

Strategic applications of gene expression: from drug discovery/development to bedside.Semantic proximity Read ↗

Harnessing AI to fuse phenotypic signatures for drug target identification: progress in computational modeling.Semantic proximity Read ↗

A novel translational in-silico indication discovery framework identifies indications and predictive biomarkers for cenerimodSemantic proximity Read ↗

High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need.Semantic proximity Read ↗

The landscape of cancer rewired GPCR signaling axesSemantic proximity Read ↗

Pathway impact analysis (PIS) for robust and comprehensive interpretation of differentially expressed genes (DEGs)Semantic proximity Read ↗

DSigDB: drug signatures database for gene set analysis.Semantic proximity Read ↗

Personalized Multi-Drug Combinations in Breast Cancer Treatment Using Individual Pattern of Perturbed Gene Expression and Drug SignaturesSemantic proximity Read ↗

The NCATS BioPlanet – An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical GenomicsSemantic proximity Read ↗

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.